Parambir S. Dulai

Parambir S. Dulai

Auto-generated profile, based on publicly available information

Parambir S. Dulai

Division of Gastroenterology and Hepatology, Feinberg School of Medicine, Northwestern University, Chicago, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDParambir S. Dulai
Parambir S. Dulai
SSSiddharth Singh
Siddharth Singh
NCNiels Vande Casteele
Niels Vande Casteele
BBBrigid S. Boland
Brigid S. Boland
JRJesus Rivera-Nieves
Jesus Rivera-Nieves
WSWilliam J. Sandborn
William J. Sandborn

1 September 2018 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
NNNeeraj Narula
Neeraj Narula
FPFarhad Peerani
Farhad Peerani
JMJoseph Meserve
Joseph Meserve
GKGursimran Kochhar
Gursimran Kochhar
KCKhadija Chaudrey
Khadija Chaudrey
PDParambir S. Dulai
Parambir S. Dulai
Active UC were included. Primary effectiveness outcomes were cumulative rates of clinical remission (resolution of all UC-related symptoms) and endoscopic remission (Mayo endoscopic sub-score 0). Key secondary effectiveness outcomes included cumulative rates of corticosteroid-free remission and deep remission (clinical remission and endoscopic remission). Cox proportional hazard analyses were used to identify independent predictors of treatment effectiveness. Non-response imputation (NRI) sensitivity analyses were performed for effectiveness outcomes. Key safety outcomes were rates of serious infection, serious adverse events, and colectomy. RESULTS: We included 321 UC patients (71% prior TNFα antagonist exposure, median follow-up 10 months). The 12-month cumulative rates of clinical remission and endoscopic remission were 51% and 41%, respectively. Corresponding rates for corticosteroid-free remission and deep remission were 37% and 30%, respectively. Using NRI, 12-month rates were 20% (n= 64/321) for clinical remission, 17% (n=35/203) for endoscopic remission, 15% (n=30/195) for corticosteroid-free remission, and 14% (n= 28/203) for deep remission. A majority of the patients without adequate follow-up at 12 months who were deemed non-responders using NRI had already achieved clinical remission (n= 70) or a significant clinical response (n=36) prior to 12 months. VDZ discontinuation prior to 12 months was observed in 91 patients, for lack of response (n=56), need for surgery (n=29), or adverse event (n=6). On multivariable analyses, prior exposure to a TNFα antagonist was associated with a reduced probability of achieving clinical remission (HR 0.53, 95% CI 0.38–0.75) and endoscopic remission (HR 0.51, 95% CI 0.29–0.88). Serious adverse events and serious infections were reported in 6% and 4% of patients, respectively. Overall cumulative rates of colectomy over 12 months were 13%, with lower rates observed in patients naive to TNFα antagonist therapy (2%) than those who had been exposed to TNFα antagonists (19%). CONCLUSION: In this large real-world cohort we observed that VDZ was well tolerated and effective in achieving key clinical outcomes....

1 September 2018 in Gastroenterology
Verified
Journal Article
Open access
PDF file
PDParambir S. Dulai
Parambir S. Dulai
BBBrigid S. Boland
Brigid S. Boland
SSSiddharth Singh
Siddharth Singh
KCKhadija Chaudrey
Khadija Chaudrey
JKJenna L. Koliani-Pace
Jenna L. Koliani-Pace
CCCharlie Cao
Charlie Cao
Background & Aims As more treatment options for inflammatory bowel diseases become available, it is important to identify patients most likely to respond to different therapies. We created and validated a scoring system to identify patients with Crohn’s disease (CD) who respond to vedolizumab. Methods We collected data from the GEMINI 2 phase 3 trial of patients with active CD treated with vedolizumab for 26 weeks (n = 814) and performed logistic regression analysis to identify factors associated with clinical, steroid-free, and durable remission (derivation set). We used these data to develop a clinical decision support tool, which we validated using data from 366 participants in a separate clinical practice observational cohort of patients with active CD treated with vedolizumab for 26 weeks (the VICTORY cohort). We evaluated the ability of this tool to identify patients in clinical remission or corticosteroid-free remission, or those with mucosal healing (MH), clinical remission with MH, or corticosteroid-free remission with MH after vedolizumab therapy using receiver operating characteristic area under the curve (AUC) analyses. The primary outcome was to develop and validate a list of factors associated with achieving remission by vedolizumab in patients with active CD. Results In the derivation analysis, we identified absence of previous treatment with a tumor necrosis factor antagonist (+3 points), absence of prior bowel surgery (+2 points), absence of prior fistulizing disease (+2 points), baseline level of albumin (+0.4 points per g/L), and baseline concentration of C-reactive protein (reduction of 0.5 points for values between 3.0 and 10.0 mg/L and 3.0 points for values >10.0 mg/L) as factors associated with remission. In the validation set, our model identified patients in clinical remission with an AUC of 0.67, patients in corticosteroid-free remission with an AUC of 0.66, patients with MH with an AUC of 0.72, patients in clinical remission with MH with an AUC of 0.73, and patients in corticosteroid-free clinical remission with MH with an AUC of 0.75. A cutoff value of 13 points identified patients in clinical remission after vedolizumab therapy with 92% sensitivity, patients in corticosteroid-free remission with 94% sensitivity, patients with MH with 98% sensitivity, patients with clinical remission and MH with 100% sensitivity, and patients with corticosteroid-free clinical remission with MH with 100% sensitivity. Conclusions We developed and validated a scoring system to identify patients with CD most likely to respond to 26 weeks of vedolizumab therapy. Further studies are needed to optimize its accuracy in select populations and determine its cost-effectiveness.

24 April 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
EYEdward Yang
Edward Yang
NPNicola Panaccione
Nicola Panaccione
NWNatalie Whitmire
Natalie Whitmire
PDParambir S. Dulai
Parambir S. Dulai
NCNiels Vande Casteele
Niels Vande Casteele
RBRobert Battat
Robert Battat
Summary: Background: Biologic therapies in patients with Crohn's disease often yield low clinical and endoscopic remission rates. After multiple failed therapies, combining two biologic therapies is possibly the sole medical alternative to recurrent surgery. However, data on this approach are limited.Aims: To assess the efficacy and safety of concomitant use of two biologic therapies in the largest cohort to date of refractory Crohn's disease patients.Methods: Data were extracted from Crohn's disease patients started on dual biologic therapy at two referral centres. Biologics utilised include infliximab, adalimumab, vedolizumab, ustekinumab, certolizumab and golimumab. The primary outcome was endoscopic improvement (>50% reduction in Simplified Endoscopic Score‐Crohn's disease [SES‐CD] or explicitly stated). Endoscopic remission (SES‐CD < 3 or stated), clinical response (Crohn's disease–patient‐reported outcome‐2 score [PRO2] reduced by 8), clinical remission (PRO2 < 8), and C‐reactive protein (CRP) were also assessed.Results: A total of 22 patients with 24 therapeutic trials of dual biologic therapy were identified. The majority of patients had prior surgical resections (91%), stricturing (59%) or penetrating (36%) phenotype, and perianal fistulas (50%). Median number of prior failed biologics was 4. Endoscopic improvement occurred in 43% of trials and 26% achieved endoscopic remission. Fifty per cent had clinical response and 41% achieved clinical remission. There were significant post‐treatment reductions in median SES‐CD (14.0 [12.0‐17.5] to 6.0 [2.5‐8.0], P = 0.0005], PRO‐2 (24.1 [20.3‐27.0] to 13.4 [4.6‐21.8], P = 0.002] and CRP (17.0 [11.0‐24.0] to 9.0 [4.0‐14.0], P = 0.02). Presence of perianal fistulas decreased from 50% to 33%. Adverse events occurred in 13% of trials.Conclusion: Dual biologic therapy was associated with clinical, biomarker and endoscopic improvements in selected patients with refractory Crohn's disease who failed multiple biologics. Further studies are needed to validate this approach.

3 October 2023 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
KDKhushdeep Dharni
Khushdeep Dharni
ASArshdeep Singh
Arshdeep Singh
SSSonika Sharma
Sonika Sharma
VMVandana Midha
Vandana Midha
KKKirandeep Kaur
Kirandeep Kaur
ASAjit Sood
Ajit Sood

1 July 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
JMJoseph Meserve
Joseph Meserve
SASatimai Aniwan
Satimai Aniwan
JKJenna L. Koliani-Pace
Jenna L. Koliani-Pace
PSPreeti Shashi
Preeti Shashi
AWAaron Weiss
Aaron Weiss
PDParambir S. Dulai
Parambir S. Dulai
There are few real-world data on the safety of vedolizumab for treatment of Crohn's disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious and non-infectious adverse events in clinical practice. We performed a retrospective review of data from a multicenter consortium database (from May 2014 through June 2017). Infectious and non-infectious adverse events were defined as those requiring antibiotics, hospitalization, vedolizumab discontinuation, or resulting in death. Rates were quantified as proportions and events per 100 patient years of exposure (PYE) or follow up (PYF). We performed multivariable logistic regression analyses to identify factors significantly associated with events and reported as odds ratios (OR) with 95% CIs. Our analysis comprised 1087 patients (650 with CD and 437 with UC; 55% female; median age, 37 years) with 861 PYE and 955 PYF. Infections were observed in 68 patients (6.3%; 7.9 per 100 PYE, 7.1 per 100 PYF); gastrointestinal infections (n = 31, 2.4 per 100 PYE, 2.2 per 100 PYF) and respiratory infections (n = 14, 1.6 per 100 PYE, 1.5 per 100 PYF) were the most common. Arthralgias were the most common non-infectious adverse events (n = 31, 2.9%; 3.6 per 100 PYE). Two patients developed malignancies (squamous cell skin cancer and colorectal cancer; 0.23 per 100 PYE, 0.21 per 100 PYF). Active smoker status (OR, 3.39) and number of concomitant immunosuppressive agents (corticosteroids or immunomodulators; OR, 1.72 per agent) used were independently associated with infections. In a retrospective cohort study of patients with IBD, we found vedolizumab to be well tolerated with an overall favorable safety profile. Active smoking and concomitant use of immunosuppressive agents were independently associated with infections.